Immune dysfunction and chronic inflammation following spinal cord injury

Spinal Cord

Volumn 53, Issue 1, 2015, Pages 14-18

  Allison, D J ^a   Ditor, D S ^a  

^a BROCK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BIBLIOGRAPHIC DATABASE; COMPLICATION; HUMAN; IMMUNE SYSTEM DISEASES; INFLAMMATION; SPINAL CORD INJURY; STATISTICS AND NUMERICAL DATA;

ANIMALS; DATABASES, BIBLIOGRAPHIC; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; SPINAL CORD INJURIES;

EID: 84940468258     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2014.184     Document Type: Review

References (53)

1. Davies AL, Hayes KC, Dekaban GA. Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1384-1393.
2. Hayes KC, Hull TCL, Delaney GA, Potter PJ, Sequeira KAJ, Campbell K et al. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 2002; 19: 753-761.
3. Gibson a E, Buchholz C, Martin Ginis K. C-Reactive protein in adults with chronic spinal cord injury: increased chronic inflammation in tetraplegia vs paraplegia. Spinal Cord 2008; 46: 616-621.
4. Liang H, Mojtahedi MC, Chen D, Braunschweig CL. Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury. Arch Phys Med Rehabil 2008; 89: 36-41.
5. Segal J, Gonzales E, Yousefi S, Jamshidipour L, Brunnemann S. Circulating Levels of IL-2R, ICAM-1, and IL-6 in Spinal Cord Injuries. Arch Phys Med Rehabil 1997; 78: 44-47.
6. Cruse JM, Keith JC, Bryant ML, Lewis RE. Immune system-neuroendocrine dysregulation in spinal cord injury. Immunol Res 1996; 15: 306-314.
7. Held KS, Steward O, Blanc C, Lane TE. Impaired immune responses following spinal cord injury lead to reduced ability to control viral infection. Exp Neurol 2010; 226: 242-253.
8. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injuryinduced immune deficiency syndrome. Nat Rev Neurosci 2005; 6: 775-786.
9. Lucin KM, Sanders VM, Jones TB, Malarkey WB, Popovich PG. Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. Exp Neurol 2007; 207: 75-84.
10. Cruse JM, Lewis RE, Bishop GR, Kliesch WF, Gaitan E. Neuroendocrine-immune interactions associated with loss and restoration of immune system function in spinal cord injury and stroke patients. Immunol Res 1992; 11: 104-116.
11. Campagnolo DI, Dixon D, Schwartz J, Bartlett JA, Keller SE. Altered innate immunity following spinal cord injury. Spinal Cord 2008; 46: 477-481.
12. Myers J, Lee M. Cardiovascular disease in spinal cord injury. Am J Phys Med Rehabil 2007; 86: 142-152.
13. Gorgey AS, Gater DR. Prevalence of obesity after spinal cord injury. Top Spinal Cord Inj Rehabil 2007; 12: 1-7.
14. Cragg JJ, Noonan VK, Dvorak M, Krassioukov A, Mancini GBJ, Borisoff JF. Spinal cord injury and type 2 diabetes: results from a population health survey. Neurology 2013; 81: 1864-1868.
15. Craig a, Tran Y, Middleton J. Psychological morbidity and spinal cord injury: a systematic review. Spinal Cord 2009; 47: 108-114.
16. Kennedy P, Rogers BA. Anxiety and depression after spinal cord injury: a longitudinal analysis. Arch Phys Med Rehabil 2000; 81: 932-937.
17. Siddall PJ, Mcclelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003; 103: 249-257.
18. Carr DJ. Neuroendocrine peptide receptors on cells of the immune system. Chem Immunol 1992; 52: 84-105.
19. Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem 2006; 99: 1073-1087.
20. Jones TB, Basso DM, Sodhi A, Pan JZ, Hart RP, MacCallum RC et al. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J Neurosci 2002; 22: 2690-2700.
21. Teasell RW, Arnold JM, Krassioukov A, Delaney GA. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. Arch Phys Med Rehabil 2000; 81: 506-516.
22. Schmid A, Huonker M, Stahl F, Barturen JM, König D, Heim M et al. Free plasma catecholamines in spinal cord injured persons with different injury levels at rest and during exercise. J Auton Nerv Syst 1998; 68: 96-100.
23. Iversen PO, Hjeltnes N, Holm B, Flatebo T, Strom-Gundersen I, Ronning W et al. Depressed immunity and impaired proliferation of hematopoietic progenitor cells in patients with complete spinal cord injury. Blood 2000; 96: 2081-2083.
24. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002; 20: 125-163.
25. Campagnolo DI, Bartlett JA, Chatterton R, Keller SE. Adrenal and pituitary hormone patterns after spinal cord injury. Am J Phys Med Rehabil 1999; 78: 361-366.
26. Cruse JM, Lewis RE, Roe DL, Dilioglou S, Blaine MC, Wallace WF et al. Facilitation of immune function, healing of pressure ulcers, and nutritional status in spinal cord injury patients. Exp Mol Pathol 2000; 68: 38-54.
27. Huang TS, Wang YH, Lee SH, Lai JS. Impaired hypothalamus-pituitary-adrenal axis in men with spinal cord injuries. Am J Phys Med Rehabil 1998; 77: 108-112.
28. Wang YH, Huang TS. Impaired adrenal reserve in men with spinal cord injury: results of low- and high-dose adrenocorticotropin stimulation tests. Arch Phys Med Rehabil 1999; 80: 863-866.
29. Nicholas JJ, Streeten DH, Jivoff L. A study of pituitary and adrenal function in patients with traumatic injuries of the spinal cord. J Chronic Dis 1969; 22: 463-471.
30. Lee W-J, Wang Y-H, Su C-T, Chen S-J, Li Y-W, Huang T-S. Adrenal gland volume after spinal cord injury. Am J Phys Med Rehabil 2002; 81: 483-488.
31. Street JT, Noonan VK, Cheung A, Fisher CG, Dvorak MF. Incidence of acute care adverse events and long-term health-related quality of life in patients with TSCI. Spine J. (e-pub ahead of print 26 August 2013; doi:10.1016/j.spinee.2013.06.051).
32. Institute RH. Near Term Focus. Available at: http://www.rickhanseninstitute.org/51-what-we-do/what-we-do/264-near-term-focusAccessed: 6 May 2014 2013.
33. Chaudhry R, Madden-fuentes RJ, Ortiz TK, Balsara Z, Tang Y, Nseyo U et al. Inflammatory response to Escherichia coli urinary tract infection in the neurogenic bladder of the spinal cord injured host. J Urol 2014; 191: 1454-1461.
34. Jiang L, Dai Y, Cui F, Pan Y, Zhang H, Xiao J et al. Expression of cytokines, growth factors and apoptosis-related signal molecules in chronic pressure ulcer wounds healing. Spinal Cord 2014; 52: 145-151.
35. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445.
36. Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 2010; 318: 69-78.
37. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
38. Bełtowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003; 9: RA55-RA61.
39. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
40. Müller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-812.
41. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia 2002; 45: 151.
42. De Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004; 279: 17070-17078.
43. Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001; 276: 25889-25893.
44. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
45. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25-46.
46. Sluzewska A. Indicators of immune activation in depressed patients. Adv Exp Med Biol 1999; 461: 59-73.
47. Uçeyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007; 132: 195-205.
48. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci 1995; 57: 1011-1026.
49. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 1991; 259: 988-996.
50. Maier SF, Goeler LE, Fleshner M, Watkins LR. The role of the vagus nerve in cytokineto-brain communication. Ann NY Acad Sci 1998; 840: 289-300.
51. Fukuoka H, Kawatani M, Hisamitsu T, Takeshige C. Cutaneous hyperalgesia induced by peripheral injection of interleukin-1 beta in the rat. Brain Res 1994; 657: 133-140.
52. Oxenkrug GF. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci 2010; 47: 56-63.
53. Pitchford S, Levine JD. Prostaglandins sensitize nociceptors in cell culture. Neurosci Lett 1991; 132: 105-108.